ѪçҺ  
Hight light ͤ : Һ :
óҸԡŧ ѪçҺ շ 17 (2550) Ѻ 3

´
¹ :  TJHP
Ѻ :  3/17 
ѹ :  1 .. 2007
ӹǹҪ :  3641
   

No3Vol17P177-184.pdf
Ҵ :  811,387
Դ :  application/pdf
ǹŴ :  900
   
 
óҸԡŧ ѪçҺ շ 17 (2550) Ѻ 3

ѪçҺ 2555 շ 22 Ѻ 3    
Ťҡҹ硷͹ԡѺ¹͡    
鹷عµçҡ´բͺ觪ҧᾷ㹻    
Ѵҹ෤ԤèѺ㹧ҹѪ    
þѲ红лżšúԺŷҧѪͼ ëͿͤ    
ԷԼŢͧкѧŴعçͧ㹼·ѺҤá    
þѲкѧԴҡ֧ʧҡ    
õԴдѺ͵ԹԹʹ·Ѻ㹡 ACEIs / ARBs: ó֡Ҽäѧäҹ    
ҵǷҧѡẺص㹼¡ҡäʹʹºѹ    
´ҹçҺԷ    
óҸԡŧ ѪçҺ 2550 Ѻ 17 ()    
šзҹͨӡѴŴѹʹçҺԷ    
ŤҡѡҷѴҡúԺŷҧѪ ͼá    
鹷عèѴФҴ͹ҧкШẺٹԵ    
ûԹŧҹͺѵ㹷ջѵѪ    
ѡʺҡŴѹʹ statins Ѻ fibrates 㹼¹͡    
ûѺҴ㹼·ǡóӧҹͧ䵺ͧ : ҧҧѪŹʵѪʵ    
ҢѺäʫ    
֡ҡ÷ӧҹ㹧ҹԡèҼ¹͡    
ººҴ͹ҧҡ͹ѧþѲкʹ㹡    
èѴûѭǡѺҷ辺ͼáѪûШͼ    
Ţͧú١ͧдѺӵʹ㹼äҹԴ 2    
Ţͧآ֡ҵẺἹʹҹآҾ͡ûѺ¹ĵԡôŵͧ мšѡҢͧäԹԴ    
Infusion Times Does Matter!    
ä : Deferasirox    
ä : Deferiprone    
Medication Reconciliation    
ԷԾŢͧԨҧõҴͷȹ㹼ԵѳáŴ˹ѡ    
ûԹٹآҾ : ѭǡѺФ֧㨢ͧԡ    
㹡ѡäҹԴѺзҹѺäǺдѺӵʹ : ó֡ Թԡá    
šФйӡҾ㹼ä״ͤسҾԵҹآҾ    
ԹԨ·ҧѪ Don't Flip-Flop!    
ǷҧѡҴҵҹͪաóԴ    
Ӫᨧ㹡˹¡Ե֡ҵͧҡԪҡ    
ä    
ԹԨ·ҧѪ    
࿵չʵ: ԨԧسҾ    
ѡɳТͧҡ֧ʧҡҵҹ秢ͧ·ѺѡçҺ    
ǹͧ㹡úԡäѴͧäҹ: 㹺ԺͧٹآҾ    
ŢͧúԺŷҧѪ¡͡ҹ㹼äҹ    
ѾͧѧԴڡҧ    
ԷԾŨҡٻẺسѡɳТͧҹҵ͡áѺԡ: ԷԾŢͧáӡѺҡѵػʧë    
óҸԡŧ ѪçҺ շ 18 (2551) Ѻ 1    
óҸԡŧ ѪçҺ 2551 շ 18 Ѻ 2    
õǨѴҴáШҤҷҨѺҧçҺѰ㹻 : ó֡ҫ͡ķк͹ Renin-Angiotensin (ACE) Inhibitors    
ѹм١ѹ: ѹҧѧ ˵ؼԧѲͧëѡҵͧͧҡ٧ط纻´äѧ㹪Ѵ˹㹡ا෾ҹ    
þѲСԧԹʴҡ͡áӡѺشͺõ駤: ÷ͺ㹼СûԹдѺҡ㹡ҹ    
ҵҹŪվͻͧѹõԴͨҡüҵѴкҧԹ    
ҷ˹ҷФԴ繢ͧѪçҺŵ͡ԡ    
Big Dose or Small Dose!    
Review of Treatment Options for multidrug-Resistant pesudomonas aeruginosa    
ä : Doripenem    
óҸԡŧ ѪçҺ 2551 շ 18 Ѻ 2    
ԷԼкҷͧѪ㹷ҢԪҪվ㹡ôżäҹԴ 2 ͼ    
ŢͧùкШ¹ẺٹԵçҺŪ    
ǨûԺѵԧҹлҳҹԡѪçҺŪ    
ԷԼŢͧ Hospital Information Management ҹѪ    
ԹԨ·ҧѪ : What is Missing in Drug Use Process?    
ä : Ibandronic Acid    
óҸԡŧ ѪçҺ 2552 շ 19 Ѻ (Ҥ 2552)    
ԷԼŢͧþѲкʹ㹡ŴعçФҴ͹ҧ㹼ä秷Ѻѡ    
˵СѺͧᾷ㹡觵ǨԴдѺҡѹѡ㹧ҹԺŷҧѪ¹͡    
ѭҷԴҡ㹼äѹԵ٧    
ûԹҵðҹʹ´ҹçҺŪ    
þѲк§ҹҴ͹ҧ    
ûԹšûءëͿ͡㹧ҹԺŷҧѪ Թԡͪ    
ûԹšúäѧçҺࢵҤҧ ѧѴӹѡҹѴзǧҸóآ    
ĵԡФ㨢ͧ黡ͧ͡һԪǹЪԴ    
óҸԡŧ ѪçҺ 2552 շ 19 Ѻ 1    
šûѺ¹Ңͧҹʹ͹͹    
ŢͧЫҵͤ㹡СäǺдѺӵ㹼ҹԴ 2    
úóҡẺͧ͸ԺäѺżҹѪäԹԡ    
ѡɳТͧҡ֧ʧҡҷѡҡ÷Դ鹢ͧ    
ҹ͡ѭѡ觪ҵ : ó֡çҺŪ    
ä : ŴдѺӵʹԴѺзҹ    
óҸԡŧ ѪçҺ 2552 շ 19 Ѻ 2    
ԷԼŢͧзʷҷԹ, ëʷҷԹ ЫʷҷԹ㹼·ջԵä㨢Ҵʹм·դ§ºä㨢Ҵʹ ǪԺѵԷ    
ѡҹͤ稢ͧþԨóѡäѭçҺ: ֡Ҽšзԧҳͧ⤫չ    
ٻẺҹкСѹآҾǹ˹Ңͧ    
úԺŷҧѪ㹼¹͡աäǺѡҢͧԹ褧    
֡ҵ鹷ع (): Ѿ㹡äǺФѹԵ٧Ңͧ·ѡԡäԡԡ¹͡    
ҷͧѪ㹧ҹҹԷ    
׺鹢ŴҹԷ    
ä : Varenicline    
óҸԡŧ ѪçҺ 2552 շ 19 Ѻ 3    
Ţͧѡ⡫Ҥôзͧ١㹼    
ǹͧѪ㹡ûͧѹҴ͹ҡ㹼ͪ/ʹ    
šǹͧѪ㹡ùǷҧԺѵԡѡ㨢ҴʹºѹŧûԺѵԷҧԹԡ    
šзͧкԡµçͤ´ҹ㹼¹͡äʹʹʴԡѡҾҺŢҪ    
Ѵšӻ֡Ҵҹä״    
ù⸿ҹ㹷ҧԴ    
ä : Itopride    
֡ԧͧẺẺͧѪǪԺѵԵ͡äǺдѺӵʹբ㹼ҹԴ 2    
óҸԡŧ ѪçҺ 2554 շ 21 Ѻ 1    
óҸԡŧ ѪçҺ 2553 շ 20 Ѻ 1    
ѾҧѡҢͧä͵ºѹԴ ST Segment ¡٧ѺѡҴ Streptokinase ·ҢԪҪվçҺŪ    
HIVQUAL-T ͻԹسҾ㹡ôżͪ/ʹ ͧçҺŪ    
ѹͧҵᾷ дѺäǺäͺ״лѨ Ѻ֧㨢ͧµ͡ٴٵü    
ҵ鹷عѴе鹷عա§ͧкѵѵ    
кǹ㹡ʹͧФǺӡѺҧ´ͧлԺѵԡ÷ҧԷʵáҷԴ鹡ѺҪԡ㹿ԵʤѺ    
÷ GI Decontamination 㹼·Ѻþ¡Ѻзҹ    
Drug-Resistant Streptococcus pneumoniae: Mechanisms and Pharmacokinetic/Pharmacodynamic-Based Therapeutic Options    
Amoxicillin/Clavulanate Potassium Extended Release Tablets    
óҸԡŧ ѪçҺ 2553 շ 20 Ѻ 2    
Ѩ·ռŵͤҴ͹㹡㹤Թԡäҹ    
ͧͻԹŴкẺء㹡ŴдѺѹŤ٧ʴԡѡҾҺŢҪ㹻    
þѲҰҹŤسҾԵмŢͧѡҵͤسҾԵҹ    
֡ҡҢͧ¹͡ԷԡûСѹآҾᵡҧѹçҺŪ 2549    
ԷԾŢͧǴ㹡üԵͤȨҡͧ͢÷ҧʹʹ    
úҵҹɷ    
ä : ʹѧԴ´    
ä : Nilotinib    
óҸԡŧ ѪçҺ 2553 շ 20 Ѻ 3    
þѲҹչ鹪ԴѺзҹ: õ駵ѺСûԹҾ    
ҴԹ Ѩ·㹡÷ӹ¢ҴлѨ·觼 INR    
ԷԼФʹ¢ͧ⤵๵㹼ҹԴ 2    
Ҵͧ Pyrazinamide غѵԡóԴɵ͵Ѻ    
ûԹý֡ԺѵԧҹԪҪվҹѪʹȢͧԵ/ѡ֡ Ѫʵ鹻շ 4    
ҡѹѡ: ǷҧþѲѺäѡ    
鹷ع Сä׹عԡѡä㹼·ѺպӺѴ    
سҾԵʵШ͹äд١ع: ó֡çҺ˹    
þѲԸͧⵡҿբͧö٧ͧਹչչҡʡѴͧԸաʡѴᵡҧѹ    
ԷҢͧԵѳӨѴŧ : оԷҢͧáԸԹ    
ä : ⷹԹ ǧͺѹ Ѻä    
ä : Agomelatine    
óҸԡŧ ѪçҺ 2554 շ 21 Ѻ 2    
Ծ鹩Ѻ - ûͧѹҴ͹ҧҷԴ鹵çµ͡úԡкǹ medication reconciliation    
ѾͧþԵԹ㹼·кСѹآҾᵡҧѹ çҺԷ    
äѴͧй㹡ԡٺѪçҺἹ¹͡    
ԴҡкԡŨʵԡؤŷ 3 ҺǪѳ줧ѧçҺ    
ԷҢͧԵѳӨѴŧС⹿ʿ    
äԹ    
Calcipotriol/Betamethasone (as Dipropionate) Ointment    
äҵҹ    
óҸԡŧ ѪçҺ 2554 շ 21 Ѻ 3    
ʹٻẺͧùҹҤسҾкСѹآҾǹ˹㹻    
ûԹԷҾͧǷҧѡäԴͷҧԹǹ觼ŵ͡һԪǹ    
ѾҡǷҧ㹡ôż秷ѺպӺѴ Capecitabine Ѫ    
ûԹкѧԴҡ֧ʧҡҢͧçҺѧѴا෾ҹ    
ä (Diseases and New Drugs) Prulifiloxacin    
Է (Toxicology) Դɨҡ    
óҸԡŧ ѪçҺ 2555 շ 22 Ѻ 1    
šþѲкǨͺʹͧ¡кԡü    
ûԹšúԺŷҧѪѺä״ Ѫ㹷ԪҪվ    
Ţͧ Inotropic Agent Order Form 㹡ҩմդ§٧    
ûԹԷҾ㹡÷äͧ Alcohol Hand Rub ءҹѧԴ    
Է : ԷҢͧҷ͡ķкҷǹҧ    
ä : Ъѡͧ    
óҸԡŧ ѪçҺ 2555 շ 22 Ѻ 2    
ҵҹŪվ㹡ѡäԴ Methicillin-resistant Staphylococcus aureus    
õԴлѺҴһԪǹ㹼·ա÷ӧҹͧ䵺ͧ͹ѡҵçҺ    
ѾúԺŷҧѪ㹼äҹФѹԵ٧ѪçҺآҾӺ    
Ţͧйӻ֡Ѫ㹷żäѧҧ䵷ҧͧͧ    
ººҡ֧ʧẺºѹҡúԫԹ ẺѹѹѺẺءѹ 㹼äͧѡʺԻⵤͤ    
ŢͧдѺӵʹ㹼ҹԴ 2    
ѾͧèѴáúӺѴҹ㹼äҹٻẺ͢çҺҹ    
ûԹͧè繢ͧѡٵáúԺŷҧѪ    
ȹԹѡ֡Ѫʵͨ¸㹡ûСͺԪҪվѪ: óѪçҺ    
ԷҢͧáӨѴѪתҤͷ    
ʺóҢͧäѧ    
öдҹèѴ÷Ѿҡͧ˹ҡҹѪ çҺѧѴзǧҸóآ    
ѭҷͧҡСûҹ¡㹼äѧʺ˵ءóط 2554: ó֡ ٹ컯Ժѵԡêͼʺ    
ûԹšõԴԹҧԴѪἹ¹͡    
Oxaliplatin: ʺóҡ÷ͧҫ    
֡ͧ鹢ͧҳС¢ͧٷẺѡ    
ԷҢͧ÷ӤҴ    
ѪçҺ 2556 շ 23 Ѻ 1    
ʶҹó㹼٧: ֡ҨҡҹŤͧçҺдѺ 4    
šйӢͧѪᾷ Һмäѧ ͧеԴŢͧҷ    
лѨ·դѹѺĵԡѡҹԴѺзҹͧ¹͡Ѻԡ÷Թԡҹ    
ʹӨҡξԹ    
ԷҢͧҹ    
ѪçҺ 2556 շ 23 Ѻ 2    
֧㨵ѪʵúѳԵѡٵѪʵúѳԵ ҢԪҡúԺŷҧѪ ҡͧͧѳԵ ѧѺѭ ҹм    
֡Ҥ㹡ҢͧʧҾҸѡҷἹ¹͡çҺʧ    
ԷԾŢͧôżäѧ㹤Թԡҹ ѪѺԪҪվ    
ó֡ : Vancomycin induced Linear Immunoglobulin A Bullous Dermatosis (LABD) Vancomycin Case report    
ɨҡ乴Сôѡ    
ѪçҺ 2556 շ 23 Ѻ 3    
šþѲҡкǹûҹ¡ҼçҺ˭˹    
Դ繢ͧҢԪҪվçҺŷյͺҷöзѪäͺǾ֧    
ûԹ÷ӧҹͧ    
§ҹó֡ : ҡôիҹԴҡ    
ԷҢͧҺاʹոҵ    
Index ѪçҺ 2555 շ 22 Ѻ 3    
óҸԡŧ ѪçҺ 2557 շ 24 Ѻ 1    
ѾͧѺ鹹 ººѺٵäӹdzСԴ٤ҷӹdz    
֡ԧءͧҴ͹㹡èҢͧѪ    
ѪѹʵѺк͹§㹡ҷҧ˹ѧԴعç    
Է (Toxicology) һѡ: Сôѡ    
ѪçҺ 2557 շ 24 Ѻ 3    
ѪçҺ 2557 շ 24 Ѻ 2    
ûԹкԡ觴ǹ㹡ä㨵ºѹẺ STEMI    
þѲкš¹ŷҧᾷ㹡ԡ÷ҧᾷͧ͢¤ѭҺԡдѺ    
ó֡: ҡ֧ʧҧعçҡ L-asparaginase    
źԹ (Methemoglobinemia)    
÷ǹҡ Proton Pump Inhibitor çҺŷ˹ : ºº͹ѧôԹô¡طèѴ    
šúԺŷҧѪ СǨ֧㨢ͧ·ѺѡҴԹաõԴҧѾ    
ҡٻʨҡ Drug-induced Lupus Erythematosus    
ԷҢͧԨ͡Թ    
ѪçҺ 2558 շ 25 Ѻ 1    
þѲкͺӶẺѵѵ ٹѪʹ Ѫʵ Է§    
Medication Safety: ergotism ҡҡ ergot alkaloids    
Toxicology : Ҵ: ѪԷСù㹷ҧԴ    
ѪçҺ 2558 շ 25 Ѻ 2    
Ţͧôżҹäѧ͡ôԹ仢ͧä    
Medication Safety: ó֡ ͹ҿ硫ʨҡҷҧüҵѴ    
Toxicology : ԷҢͧáӨѴѪתʵ    
ѪçҺ 2558 շ 25 Ѻ 3    
ѴšûԺѵԧҹͧ˹ҷ㹡úԡèҼ    
Medication Safety: Drug-induced Hypersensitivity Syndrome ҡҡѹѡ    
Toxicology : ԷҢͧáӨѴ˹ѵѹ    
óҸԡŧ ѪçҺ 2559 շ 26 Ѻ 1    
ûԹõǨԴ㹼¨ԵǪ çҺž⾸    
Rilpivirine    
ԷҢͧҾ૵    
óҸԡŧ ѪçҺ 2559 շ 26 Ѻ 2    
ѾͧѵõԴ෤ԤҾٴ㹡úԺŷҧѪ¹͡ҾٴٻẺ metered dose inhaler    
Դ injection site reaction ҡ ciprofloxacin levofloxacin С    
óҸԡŧ ѪçҺ 2559 շ 26 Ѻ 3    
þѲͤ-㹡è С֡дѺФ֧㨢ͧ    
٧ҹѪȭ ͹ 1 ҹѪçҺ    
٧ҹѪȭ ͹ 2 ҹѪҹ